The argument is that antibiotics are not going to be a attractive target for any pharma, big or small. If you develop a new antibiotic that kills resistant bact

The argument is that antibiotics are not going to be a attractive target for any pharma, big or small. If you develop a new antibiotic that kills resistant bacteria effectively, it's going to be an antibiotic of last resort, heavily regulated and rarely used. Less profitable. Without government interventions to incentivize development of new antibiotics, I don't believe we'll see pharma take on the challenge alone. Meanwhile, we've seen that Hep C cures can be (extremely) profitable. See also Luxterna (gene therapy for inherited blindness).